CClinicalTrials.gg
Sign In
Enrolling by invitationNCT07525323PEARLUpdated Jul 20, 2026

EMG ss AMG In Robotic/Laparoscopic Surgery

An interventional study of AMG device and EMG in Surgery, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the mean cumulative weight-based/time-corrected rocuronium dose administered in patients undergoing robotic- or laparoscopic- assisted surgery using either acceleromyography or electromyography.

02

Conditions studied

  • Surgery
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Age > or = 18 years old
  • Patients willing to participate and provide an integrated, informed consent
  • Patients undergoing elective laparoscopic- or robotic-assisted surgical procedures
  • Anticipated surgery duration \< 300 minutes Exclusion Criteria
  • Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
  • Patients with systemic neuromuscular diseases such as myasthenia gravis.
  • Patients having surgery that would involve prepping the arm into the sterile field.
  • Patients with chronic kidney disease (eGFR \<60).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    AMG

    The anesthesia team will manage the level of block based on AMG values

    Device: AMG device

  • Active comparator
    EMG

    The anesthesia team will manage the level of block based on EMG values

    Device: EMG

Interventions

  • DeviceAMG device

    The anesthesia team will use an AMG device to monitor neuromuscular block

  • DeviceEMG

    The anesthesia team will use an EMG device to monitor neuromuscular block

06

What researchers measure

Primary outcomes

  1. Cumulative rocuronium dose

    Weight- and time-adjusted mean cumulative rocuronium dose between the AMG and EMG groups

    Time frame: Perioperative/Periprocedural

Secondary outcomes

  1. Mean sugammadex dose

    Mean sugammadex dose between the two groups

    Time frame: Perioperative/Periprocedural

  2. Number of rocuronium administrations

    Number of rocuronium administrations throughout the case,

    Time frame: Perioperative/Periprocedural

  3. Frequency of placing a peripheral nerve stimulator

    Frequency of placing a peripheral nerve stimulator

    Time frame: Perioperative/Periprocedural

  4. Depth of neuromuscular block prior to sugammadex administration

    Depth of neuromuscular block prior to sugammadex administration

    Time frame: Perioperative/Periprocedural

07

Study locations

1 site
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525323
Lead sponsor
Mayo Clinic
Responsible party
J. Ross Renew, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Apr 13, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 20, 2026

Study contacts

Johnathan Renew
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Mayo Clinic

Start the discussion